Clinical risk factors predicting genital fungal infections with sodium-glucose cotransporter 2 inhibitor treatment: The ABCD nationwide dapagliflozin audit.

Thong Ken Yan, Yadagiri Mahender, Barnes Dennis Joseph, Morris David Stuart,Chowdhury Tahseen Ahmad, Chuah Ling Ling, Robinson Anthony Michael,Bain Stephen Charles,Adamson Karen Ann,Ryder Robert Elford John, Null Null

Primary Care Diabetes（2018）

引用 40|浏览5

暂无评分

摘要

•Dapaglilfozin, an SGLT2 inhibitor, increases the risk of genital fungal infections.•Women are at much greater risk of developing genital infections with dapagliflozin.•Patients with prior genital fungal infection are also at greater risk.•Higher baseline HbA1c or BMI did not increase treatment-related genital infections.•Rates of dapagliflozin discontinuation due to genital infections were low.

查看译文

关键词

Dapagliflozin,SGLT2 inhibitor,Genital fungal infection,Genital mycotic infection,Thrush

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要